Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 03 2022
Historique:
received: 21 05 2021
revised: 07 10 2021
accepted: 22 10 2021
pubmed: 13 11 2021
medline: 8 3 2022
entrez: 12 11 2021
Statut: ppublish

Résumé

Radiation pneumonitis remains a major limitation in the radiation therapy treatment of patients with lung cancer. Functional avoidance radiation therapy uses functional imaging to reduce pulmonary toxic effects by designing radiation therapy plans that reduce doses to functional regions of the lung. Lung functional imaging has been developed that uses 4-dimensional computed tomography (4DCT) imaging to calculate 4DCT-based lung ventilation (4DCT-ventilation). A phase 2 multicenter study was initiated to evaluate 4DCT-ventilation functional avoidance radiation therapy. The study hypothesis was that functional avoidance radiation therapy could reduce the rate of grade ≥2 radiation pneumonitis to 12% compared with a 25% historical rate, with the trial being positive if ≤16.4% of patients experienced grade ≥2 pneumonitis. Lung cancer patients receiving curative-intent radiation therapy (prescription doses of 45-75 Gy) and chemotherapy were accrued. Patient 4DCT scans were used to generate 4DCT-ventilation images. The 4DCT-ventilation images were used to generate functional avoidance plans that reduced doses to functional portions of the lung while delivering the prescribed tumor dose. Pneumonitis was evaluated by a clinician at 3, 6, and 12 months after radiation therapy. Sixty-seven evaluable patients were accrued between April 2015 and December 2019. The median prescription dose was 60 Gy (range, 45-66 Gy) delivered in 30 fractions (range, 15-33 fractions). The average reduction in the functional volume of lung receiving ≥20 Gy with functional avoidance was 3.5% (range, 0%-12.8%). The median follow-up was 312 days. The rate of grade ≥2 radiation pneumonitis was 10 of 67 patients (14.9%; 95% upper CI, 24.0%), meeting the phase 2 criteria. 4DCT-ventilation offers an imaging modality that is convenient and provides functional imaging without an extra procedure necessary. This first report of a multicenter study of 4DCT-ventilation functional avoidance radiation therapy provided data showing that the trial met phase 2 criteria and that evaluation in a phase 3 study is warranted.

Identifiants

pubmed: 34767934
pii: S0360-3016(21)03070-4
doi: 10.1016/j.ijrobp.2021.10.147
pmc: PMC8863640
mid: NIHMS1756800
pii:
doi:

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

986-995

Subventions

Organisme : NCI NIH HHS
ID : R01 CA200817
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA119930
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA090301
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA128230
Pays : United States
Organisme : NCI NIH HHS
ID : K01 CA181292
Pays : United States
Organisme : NCI NIH HHS
ID : UG3 CA247605
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA090301
Pays : United States
Organisme : NIH HHS
ID : DP2 OD007044
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236857
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):325-333
pubmed: 28871982
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):332-9
pubmed: 22079735
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):691-8
pubmed: 19836159
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):562-71
pubmed: 17398028
Phys Med Biol. 2012 Apr 7;57(7):1855-71
pubmed: 22411124
Radiother Oncol. 2013 Mar;106(3):327-32
pubmed: 23453540
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):199-205
pubmed: 24725702
Med Phys. 2019 Mar;46(3):1198-1217
pubmed: 30575051
Cancer. 2020 Oct 1;126(19):4353-4361
pubmed: 32697352
Phys Med Biol. 2012 Aug 7;57(15):4827-33
pubmed: 22797602
Med Phys. 2019 Nov;46(11):5036-5046
pubmed: 31514235
Med Phys. 2018 Oct;45(10):4483-4492
pubmed: 30047588
Acad Radiol. 2012 Dec;19(12):1546-53
pubmed: 22999648
Phys Med Biol. 2010 Aug 21;55(16):4661-85
pubmed: 20671351
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1357-1365
pubmed: 30353873
Radiother Oncol. 2021 Jul;160:120-124
pubmed: 33964328
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):630-4
pubmed: 15936537
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):279-88
pubmed: 20646852
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):202-209
pubmed: 28816147
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50
pubmed: 22682812
Cancer. 1975 Sep;36(3):904-13
pubmed: 1182677
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1273-80
pubmed: 27354134
J Appl Clin Med Phys. 2017 May;18(3):144-152
pubmed: 28436107
J Cancer Res Clin Oncol. 2012 Dec;138(12):2103-16
pubmed: 22842662
Phys Med Biol. 2006 Feb 21;51(4):777-91
pubmed: 16467578
Med Phys. 2014 Jan;41(1):011910
pubmed: 24387518
Med Phys. 2021 Apr;48(4):1804-1814
pubmed: 33608933
Med Phys. 2019 May;46(5):2115-2125
pubmed: 30779353
J Nucl Med Technol. 2012 Mar;40(1):57-65
pubmed: 22282651
Br J Radiol. 2016;89(1060):20150431
pubmed: 26838950
Phys Med Biol. 2019 Feb 18;64(4):045014
pubmed: 30654352
Med Phys. 2017 Jul;44(7):3418-3429
pubmed: 28453861
N Engl J Med. 2015 Jul 16;373(3):288-90
pubmed: 26176400
Clin Oncol (R Coll Radiol). 2016 Nov;28(11):695-707
pubmed: 27637724
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):94-102
pubmed: 17321067
Med Phys. 2016 Jan;43(1):33
pubmed: 26745897
Int J Radiat Oncol Biol Phys. 1993 Jul 15;26(4):659-68
pubmed: 8330998
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Radiother Oncol. 2015 May;115(2):157-62
pubmed: 25935743
Radiother Oncol. 2016 Feb;118(2):227-31
pubmed: 26687903
Int J Comput Assist Radiol Surg. 2017 Apr;12(4):569-580
pubmed: 28058533
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
pubmed: 20171521
Radiother Oncol. 2018 Dec;129(3):494-498
pubmed: 29628292
Radiother Oncol. 2008 Apr;87(1):17-23
pubmed: 18343515
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):366-71
pubmed: 23474113
J Appl Physiol (1985). 2008 Apr;104(4):1177-84
pubmed: 18258804

Auteurs

Yevgeniy Vinogradskiy (Y)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: yevgeniy.vinogradskiy@jefferson.edu.

Richard Castillo (R)

Department of Radiation Oncology, Emory University, Atlanta, Georgia.

Edward Castillo (E)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Leah Schubert (L)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Bernard L Jones (BL)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Austin Faught (A)

Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.

Laurie E Gaspar (LE)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Jennifer Kwak (J)

Department of Radiology, University of Colorado School of Medicine, Aurora, Colorado.

Daniel W Bowles (DW)

Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado; Rocky Mountain Regional VA Medical Center, Aurora, Colorado.

Timothy Waxweiler (T)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Jingjing M Dougherty (JM)

Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.

Dexiang Gao (D)

Departments of Pediatrics and Biostatistics and Informatics, University of Colorado School of Medicine, Aurora, Colorado.

Craig Stevens (C)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Moyed Miften (M)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Brian Kavanagh (B)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Inga Grills (I)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Chad G Rusthoven (CG)

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.

Thomas Guerrero (T)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH